Calcium ions are ubiquitous signalling molecules in all multicellular organisms, where they mediate diverse aspects of intracellular and extracellular communication over widely varying temporal and spatial scales 1 . Though techniques to map calcium-related activity at a high resolution by optical means are well established, there is currently no reliable method to measure calcium dynamics over large volumes in intact tissue 2 . Here, we address this need by introducing a family of magnetic calcium-responsive nanoparticles (MaCaReNas) that can be detected by magnetic resonance imaging (MRI). MaCaReNas respond within seconds to [Ca 2+ ] changes in the 0.1-1.0 mM range, suitable for monitoring extracellular calcium signalling processes in the brain. We show that the probes permit the repeated detection of brain activation in response to diverse stimuli in vivo. MaCaReNas thus provide a tool for calcium-activity mapping in deep tissue and offer a precedent for the development of further nanoparticle-based sensors for dynamic molecular imaging with MRI.
measure [Ca
] o levels, but most existing compounds have binding constants that are too high for optimal sensing in the 0.1-1.0 mM range; like other optical probes, they are also unsuitable for typical applications in deep tissue. MRI-detectable calcium probes, which include calcium-responsive nanoparticle sensors tuned to other [Ca 2+ ] ranges, have been developed for non-invasive applications [12] [13] [14] , but none has yet been shown to reveal calcium dynamics in vivo. One of the challenges in constructing a calcium sensor suitable for monitoring [Ca 2+ ] o is the need for a sensor mechanism that transduces relatively modest analyte fluctuations into discernible changes in the image signal. Such sensitivity is particularly hard to achieve using small-molecule sensors, which usually exhibit binding isotherms that span two orders of magnitude in [Ca 2+ ] (ref. 15 ). For this reason, we sought to improve on previous approaches by exploiting the highly cooperative sensing mechanism afforded by reversible magnetic nanoparticle clustering, which can produce large changes in T 2 -weighted MRI signals over relatively narrow ionic concentration ranges 2 .
To achieve an appropriate sensitivity, a new MaCaReNa probe was engineered using synaptotagmin proteins, which are components of the synaptic neurotransmitter-release machinery that naturally respond to 0.1-1.0 mM changes in [Ca 2+ ] (ref. 1 ) and that have not previously been applied for MRI calcium sensing. Each synaptotagmin monomer contains two ~15 kDa calcium-binding C2 domains. Calcium binding to these domains promotes further complex formation with the anionic lipid phosphatidylserine (PS), a component of the plasma-membrane inner leaflet. This interaction can drive the clustering of PS-containing lipid vesicles at Ca 2+ concentrations above ~0.2 mM (ref. 16 ), suitable for monitoring [Ca 2+ ] o .
MaCaReNa sensors based on this effect were prepared by mixing the fused C2 domains of synaptotagmin 1 (C2AB) with lipid-coated iron oxide nanoparticles (LCIOs) (Fig. 1a ). The C2AB moieties were expressed and purified from bacteria 17 and the nanoparticles were prepared by coating oleate-stabilized magnetic iron oxide cores with a 7:3 mixture of phosphatidylcholine (PC) and PS (see Methods). Initial tests were performed with combinations that contained 1 nM nanoparticles (100 µ M Fe) and 2.5 µ M C2AB. Ca 2+dependent aggregation of the sensor components was measured by dynamic light scattering (DLS) in artificial cerebrospinal fluid (aCSF) with or without 1 mM Ca 2+ . The observed hydrodynamic diameters were 35 ± 1 and 262 ± 14 nm, respectively, in low versus high calcium conditions. Mg 2+ concentration changes produced no discernible effects in DLS, which demonstrates the specificity of Ca 2+ dependence ( Supplementary Fig. 1 ). Atomic force microscopy Letters Nature NaNotechNology (AFM) images further confirmed the nanoparticle aggregation in the presence of Ca 2+ (Fig. 1b) .
MaCaReNa responses were readily detectable by MRI, with a calcium-dependent increase in the strength of the contrast agent (transverse relaxivity, r 2 ) from 151 ± 15 mM −1 s −1 at 0 mM Ca 2+ to 261 ± 21 mM −1 s −1 at 1.2 mM Ca 2+ (Fig. 1c ). This increase in r 2 is consistent with the expected consequences of aggregation for magnetic nanoparticles with diameter below ~30 nm (ref. 18 ). Half-maximal r 2 changes were observed at 0.43 mM Ca 2+ . Calcium-dependent r 2 changes could not be observed in samples that contained LCIOs without C2AB, or LCIOs mixed with a C2AB variant (C2AB Ca− ) engineered to lack calcium-binding affinity ( Supplementary Fig. 2 and Supplementary Table 1 ). These controls demonstrate the specificity of calcium detection by the MaCaReNa mechanism. Raw images of samples that contain MaCaReNas or control mixtures show the corresponding T 2 -weighted MRI signal changes in each case ( Fig. 1d ). Importantly, calcium-dependent r 2 changes could be reversed by the subsequent addition of excess ethylenediaminetetraacetic acid (EDTA), and restored again by further addition of excess CaCl 2 (Fig. 1e ).
Response kinetics of the MaCaReNa probes are important for dynamic calcium sensing. To measure sensor-response times, we performed DLS experiments in which calcium concentrations were rapidly increased or decreased by the addition of Ca 2+ or a chelator, respectively, to MaCaReNa samples that again contained 1 nM LCIOs and 2.5 µ M C2AB ( Supplementary Fig. 3a ). The results indicated substantial changes in the light scattering that reflected clustering and unclustering of the sensors within the experimental dead time of ~20 s. Kinetic measurements of the LCIO-C2AB interaction on a faster timescale were obtained by measuring biolayer interferometry (BLI) changes after the rapid immersion of a surface conjugated to C2AB into a solution that contained LCIO particles ( Supplementary Fig. 3b ). The observed time intervals for half-maximal binding or dissociation of the particles were 4.9 ± 1.0 s and 4.1 ± 0.4 s, respectively. These results indicate that MaCaReNas formed from C2AB and LCIOs can achieve response rates suitable for calcium-dependent molecular-level functional MRI (molecular fMRI) on the timescale of seconds 2 .
To ascertain whether aggregated versus disaggregated probe states could be distinguished by MRI in living tissue, we intracranially injected rats over one hour with a total of 7.2 μ l of 1 nM LCIOs in the presence or absence of 2.5 µ M C2AB. To prevent the agglomeration of particles before or during brain infusion, sensors and control samples were formulated in calcium-free aCSF that contained 5 mM ethylene glycol-bis(2-aminoethylether)-N,N,N′ ,N′ -tetraacetic acid (EGTA). Volumetric analysis of the T 2 -weighted MRI scans showed detectable contrast effects over regions of 80 ± 60 µ l 3 ( Supplementary Fig. 4 ), which demonstrates the distribution of MaCaReNas over sizable measurement volumes in vivo is feasible. The region of contrast created by nanoparticle injection arose from convective spreading under the injection conditions we employed; because of parenchymal geometric constraints 19 and the relatively slow predicted diffusion of both MaCaReNa components 20 , passive transport is unlikely to contribute significantly to the probe distribution or to the separation of LCIO and C2AB species from one another. The T 2 -weighted MRI signal in areas infused 
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with MaCaReNas was considerably lower than in areas infused with LCIO only ( Fig. 2a ). A mean MRI signal decrease with respect to the background of 42 ± 4% was observed in brain areas infused with MaCaReNas; this change was significantly greater (t-test, P ≤ 0.023, n ≥ 4) than signal changes observed in areas injected with LCIOs only (21 ± 8%) or with LCIOs mixed with C2AB Ca− (24 ± 6%) ( Fig. 2b) .
These results suggest functionality of the MaCaReNa calciumresponsive mechanism in the living tissue.
To assess the ability of MaCaReNas to report dynamic changes in [Ca 2+ ] o evoked by neural activity, probes were injected intracranially into the rat striatum, followed by chemical neurostimulation using 0.6 µ l pulses of 100 mM KCl in aCSF. A similar K + infusion paradigm has been used previously to induce neural-activity changes with a radius of over 1.5 mm (ref. 21 ). In our experiments, K + stimulation produced notable signal increases exclusively within areas infused with MaCaReNas ( Fig. 3a) , consistent with the expected suppression of [Ca 2+ ] o by the stimulation and consequent decrease in r 2 due to disaggregation of the calcium sensors. Stimulus-dependent signal changes were reversible and could be repeated over multiple cycles of K + stimulation and recovery with no apparent decrease in response amplitudes over the repeated treatments ( Fig. 3b,c) . The observed rise times and decay times on the order of minutes probably reflect a mixture of K + infusion dynamics, neural-activity time courses and sensor-response characteristics. Corresponding K + -induced MRI changes could not be observed in the presence of control sensors formulated with C2AB Ca− (Fig. 3a,b) . Similarly, signal changes were not observed after mock stimulation by the infusion of aCSF supplemented by 100 mM NaCl in place of KCl (Fig. 3b ). Brain stimulation with 0.6 µ l pulses of the excitatory neurotransmitter glutamate 22 (1 mM) also produced clear and repeatable signal increases in the presence of MaCaReNa sensors that could not be observed with the C2AB Ca− control probes ( Fig. 3d and Supplementary Fig. 5 ). Neither K + nor glutamate-dependent responses could be explained by direct effects of these stimulants 
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Nature NaNotechNology on the MaCaReNas themselves ( Supplementary Fig. 6 ). These measurements, therefore, indicate the ability of MaCaReNas to report neural-activity-dependent [Ca 2+ ] o fluctuations in the absence of artefacts from endogenous blood flow or other confounding factors. Molecular fMRI signal changes induced by K + stimulation in the presence of MaCaReNas (18 ± 5%) were significantly greater than the signal changes induced by Na + infusion in the presence of MaCaReNas (t-test, P = 0.027, n = 4) or K + stimulation in the presence of control sensors formulated with C2AB Ca− (t-test, P = 0.0099, n = 4) ( Fig. 3e ). Glutamate-induced signal changes (10 ± 1%) were also significantly greater in the presence of MaCaReNas than in the presence of LCIO/C2AB Camixtures (t-test, P = 0.0008, n = 4) ( Fig. 3e ). The varying effects of K + and glutamate stimulation were also reflected by differences in the slopes of the onset of signal changes observed during and after stimulation ( Fig. 3f ). Potassium stimulation evoked a sharper rise in the MRI signal, consistent with the greater magnitude of its effect, but its decline to baseline was also faster as a percentage of its rise time (− 30 ± 4% min −1 for K + versus − 2 ± 4% min −1 for glutamate), consistent with the possibility that glutamate-induced [Ca 2+ ] o depression might persist for longer in the brain.
To probe the ability of MaCaReNas to detect more physiological neuronal activation on a faster timescale, we applied the probes in conjunction with medial forebrain bundle (MFB) electrical stimulation 23 , a neural activation paradigm used commonly in addiction research ( Fig. 4a ). Stimulation parameters chosen for the experiments were within the range of previous studies 24, 25 , and suitable for evoking robust self-stimulation behaviour in a standard operant paradigm ( Supplementary Fig. 7 ), which demonstrates their relevance to naturalistic behaviour and its underlying neurophysiology. To measure calcium responses to the stimulation, MaCaReNas were infused into the dorsal striatum and then imaged using a blockdesign paradigm 26 in conjunction with T 2 -weighted spin-echo echoplanar imaging performed with a frame rate of 0.25 Hz, which is also characteristic of conventional haemodynamic fMRI. Image-contrast changes were observed only when functional MaCaReNas were infused ipsilaterally to the stimulated MFB, and not under control conditions with the contralateral stimulation or calcium-insensitive LCIOs (Fig. 4b-d ). The magnitude of the average observed response was 13 ± 2%, comparable to the chemical stimulation paradigms of Fig. 3 , but here the response was evoked within seconds and peaked near the stimulus offset time (Fig. 4c ). This onset profile is similar to that reported previously using a closely related stimulation paradigm in conjunction with a dopamine-sensitive MRI contrast agent 24 , which reflects the possibility that activation of the MFB dopamine fibres contributes substantially to the observed calcium response.
Unlike dopamine time courses, which return to the baseline shortly after MFB stimulation, the calcium-dependent signal remained elevated above the baseline for several minutes before decreasing again, which suggests that [Ca 2+ ] o stays suppressed over this time. To determine whether this prolonged effect is truly indicative of the underlying cellular activity, we recorded single-unit activity from the dorsal striatum during the same stimulus paradigm as used for the molecular fMRI experiments. Measurements revealed that many striatal neurons experienced firing-rate changes that persisted for about 2-3 min after the MFB stimulus, which parallels the MRI results ( Fig. 4e ). Though subsets of the neuronal population showed increases or decreases in activity, the overall population showed a 26% increase in the mean firing rate, which was highly significant with t-test P < 0.0001 ( Fig. 4f ). Comparisons between pre-and post-stimulus average spike rates were highly significant in all three groups, with t-test P < 0.0001. The trends in neural spike rates we observed were qualitatively comparable to previously published recordings that demonstrated protracted changes in neuronal firing in multiple brain regions after MFB stimulation 27, 28 . These results thus suggest that the time course of MaCaReNa responses primarily reflects the natural dynamics of neural activity elicited by MFB stimulation, and perhaps arise in part from postsynaptic striatal dopamine-receptor activation, rather than from the kinetic characteristics of the sensors themselves.
Our findings thus demonstrate a molecular-imaging paradigm suitable for monitoring [Ca 2+ ] o dynamics in the interstitial space of the brain over biologically relevant intervals that range from seconds to hours 4, 10 . In doing so, the work extends an emerging set of methods available for molecular fMRI 2 . In addition, the results establish that 
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MRI sensors based on magnetic nanoparticle aggregation can function reversibly in complex biological tissue, a principle that can apply to mechanistically related probes 29 . Though the biological side effects of MaCaReNas were not ruled out explicitly, the probe doses used here were too low to perturb substantially the [Ca 2+ ] o homeostasis through buffering (the Ca 2+ -binding capacity of the injected sensors was < 10 µ M), and previous studies found that coated nanoparticles in the applied concentration range exhibit little toxicity 30 .
Future applications of MaCaReNa imaging could include the characterization of extracellular calcium signalling in animal models, mechanisms that govern [Ca 2+ ] o fluctuations and relationships of extracellular calcium to diverse biological phenomena in the brain and other organs. Future work should also address current challenges of the method, such as a need for faster measurements and a more-rigorous quantification of [Ca 2+ ] o . Building on the initial results presented here, MaCaReNas could be optimized further for neuroimaging applications by tuning their Ca 2+ affinities more precisely to concentrations in the 0.8-1.2 mM range and by reducing the particle size to promote faster response kinetics and an improved probe distribution. Minimally invasive or fully non-invasive probe-delivery methods, such as those that employ ultrasoundassisted or receptor-mediated trans-blood-brain barrier transport, will also be important for applications that take full advantage of the whole-brain imaging capabilities of MRI.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41565-018-0092-4.
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Nature NaNotechNology Methods Animals. All animal experiments were performed after the approval of the Massachusetts Institute of Technology (MIT) Committee on Animal Care, and in accordance with the institutional and National Institutes of Health (NIH) guidelines. A total of 26 rats were used for the data presented in this paper. All the animals were male Sprague-Dawley rats, 8-10 weeks of age; they were purchased from Charles River Laboratories. The animals were housed and maintained on a 12 h light/dark cycle with ad libitum access to food and water. Sample sizes for all the animal experiments were chosen such that between-group comparisons provided a power of 0.8 when detecting 10% signal differences between the groups using two-tailed t-tests with α = 0.05, assuming within-group standard deviations of approximately 5%.
AFM. The sample solution (30 μ l) was deposited onto a V-1 quality muscovite mica disc (Electron Microscopy Sciences) freshly cleaved using adhesive tape. The mica was incubated in a Petri dish for 30 min, rinsed with 1 ml of deionized water and then dried initially with compressed air. The mica was further dried overnight at room temperature and protected from dust contamination. The prepared sample was measured in air using a Multimode 8 atomic force microscope equipped with a SCANASYST-AIR cantilever (Bruker Instruments) operated in the soft tapping mode.
DLS.
DLS was performed using a DynaPro DLS system (Wyatt Technology) with a 1 s integration time at 22 °C. The laser power was adjusted so that all the samples gave a scattering light intensity on the order of 10 5 counts s −1 .
Preparation of LCIOs. l-α -phosphatidylcholine (4.5 mg) from hen egg (Avanti Polar Lipids) and 1.5 mg of l-α -phosphatidylserine from porcine brain (Avanti Polar Lipids) were dissolved in 250 μ l of chloroform. An aliquot (50 μ l) of an iron oxide nanoparticle (10 nm with an oleic acid coating in chloroform, from Ocean NanoTech) solution (5 mg Fe ml -1 ) was mixed with the lipid solution and the mixture was thoroughly evaporated to obtain an even brown lipid film. HEPES buffer (200 μ l, 10 mM, pH 7.4) was added into the lipid film and sonicated until the entire brown layer was homogeneously dispersed into the buffer to yield a brown transparent solution. The mixture was inserted into a magnetic μ column, placed into a µ MACS magnetic separator (Miltenyi Biotec) and washed four times with buffer aliquots (50 μ l). The purified solution was eluted by removing the column from the magnet and adding 150 µ l of the buffer. The eluate was centrifuged at 6,000g for 10 min to remove large aggregates and then the supernatant was filtered using a 0.1 µ m syringe top filter. The final resulting concentration of LCIOs was quantified from the absorbance at 450 nm using a molar absorbance coefficient of ε 450 = 690 (M Fe) −1 cm −1 , which in turn was determined by a colorimetric assay using bathophenanthrolinedisulfonic acid 31 .
Purification of C2AB. Escherichia coli (BL21) that express 6xHis-tagged C2AB were generously provided by J. Lee and J. T. Littleton (MIT). 6xHis-tagged C2AB was purified according to published procedures 17 , with minor modifications. Briefly, E. coli cells that harboured the tagged C2AB gene were grown in 5 ml of lysogeny broth (LB) medium with 50 μ g ml -1 of ampicillin at 37 °C overnight. LB/ampicillin medium (100 ml) was inoculated with 1 ml of the overnight culture and grown to OD 600 = 0.6 for 2-3 h at 37 °C. Protein expression was induced by adding 1 ml of 1 M isopropyl-β -d-1-thiogalactopyranoside (IPTG) during vigorous shaking. The cells were harvested 4 h after adding IPTG by centrifugation at 6,000g for 20 min at 4 °C. The obtained cell pellet (~1 g) was stored at − 80 °C overnight and subsequently lysed by the addition of 5 ml of BugBuster reagent (EMD Millipore), 10 μ l of Lysonase Bioprocessing Reagent (EMD Millipore) and 50 μ l of P8849 protease inhibitor cocktail (Sigma-Aldrich). The cell lysate was vortexed quickly and nutated gently for 15 min at room temperature. The mixture was then centrifuged at 12,000g for 20 min at 4 °C to pellet the insoluble material. The collected supernatant was added to a column partially filled with 1 ml of Ni-NTA Superflow Resin (Qiagen) previously pre-equilibrated with binding buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, pH 8.0). The loaded column was nutated for 1 h at 4 °C to promote protein binding. The resin was washed four times using 5 ml of wash buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole, 0.1% Tween 20, pH 8.0) and four times using 5 ml of the wash buffer without Tween 20. Then, the protein was eluted by the addition of 1 ml of elution buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 250 mM imidazole, pH 8.0). The eluate was concentrated and exchanged into experimental buffer conditions using a 10 K Amicon Ultra filter (EMD Millipore). The protein purity was assessed by SDS-PAGE, and protein concentration was determined using the Pierce 660 nm Protein Assay (Thermo Fisher Scientific).
Cloning of C2AB Ca− . The calcium-binding sites of C2AB were determined from structural data 32 and Ca 2+ -binding residues were mutated to alanine in silico using Serial Cloner software (www.serialbasics.free.fr). The resulting mutant sequence was ordered as a synthetic DNA fragment (Integrated DNA Technologies). The fragment was ligated into the original C2AB plasmid using NEBuilder assembly enzymes (New England Biolabs).
BLI. BLI was performed on an Octet Red BLI instrument (Pall ForteBio). C2AB was attached to the sensor probes via adhesion to an Ni-NTA-coated tip. Binding kinetics were monitored after submersion of the C2AB-bound tip in aCSF that contained 1.2 mM Ca 2+ and 1 nM LCIOs (100 µ M Fe). The dissociation rates were measured by then transferring the tips to calcium-free aCSF after briefly washing excess LCIOs off in complete aCSF. Kinetics data were analysed using customwritten MATLAB (MathWorks) scripts.
In vitro MRI. In vitro MRI was performed with a 7 T Biospec MRI scanner (Bruker). Samples were arrayed into bisected 384-well microtiter plates and imaged using a volume tranceiver coil. A multislice multiecho pulse sequence was used to obtain T 2 -weighted images, with typical parameters including matrix size = 256 × 256, field of view (FOV) = 5 cm × 5 cm, slice thickness = 2 mm, repetition time (TR) = 2,000 ms, echo spacing with echo time (TE) = 8 ms, and number of echoes = 30. T 2 values were obtained by exponential fitting to MRI intensities as a function of TE. r 2 values were defined by two-point measurements of the slopes between 1/T 2 of aCSF without nanoparticles and 1/T 2 of aCSF that contained 100 μ M Fe nanoparticles, and are reported as the mean and s.e.m. of measurements performed in triplicate. r 2 titrations were performed in aCSF with varying concentrations of calcium. Measurement of the reversibility of r 2 changes was performed in 10 mM HEPES, 150 mM NaCl, pH 7.4, with the addition of excesses of CaCl 2 and EDTA to achieve an alternation between 0 mM and 1 mM net Ca 2+ concentrations. The use of a lower ionic strength buffer for this experiment limited the effects of the accumulation of CaCl 2 and EDTA throughout the procedure, but resulted in slightly greater r 2 values than observed in aCSF under high calcium conditions.
Ex vivo MRI and analysis of nanoparticle infusion.
To measure brain volumes affected by the infusion of nanoparticle mixtures, animals were injected with 200/10 mg/kg ketamine/xylazine after MRI experiments and cardiac perfused with cold phosphate-buffered saline with 10 units ml -1 heparin followed by 4% paraformaldehyde. The animals were then prepared for high-resolution post-mortem imaging according to published procedures 33 . The animals were decapitated and tissue was stripped from the skull before incubating in 1 mM gadolinium diethylenetriaminepentaacetic acid for 96 h at 4 °C. The resulting fixed, contrast-enhanced samples were then scanned with 100 µ m isotropic resolution using a gradient echo-pulse sequence implemented with TR/TE = 250/35 ms on the 7 T scanner. Rat brains were manually segmented for analysis and areas of hypointensity were further segmented from the three-dimensional (3D) data sets by placing a seed value at the centre of the injection area with a threshold at ± 10% of the seed signal intensity. All the 3D analysis was done using the segmentation editor in FIJI (http://fiji.sc/).
Cannula implantation and brain infusion of nanoparticle mixtures.
The nanoparticle mixtures formulated for brain infusion included 1 nM LCIOs (100 µ M Fe) alone or mixed with 2.5 µ M C2AB protein (for MaCaReNas) or 2.5 µ M C2AB Ca− (for the control LCIO/C2AB Ca− mixtures). All of these mixtures were formulated in calcium-free aCSF (125 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 , 1.25 mM NaH 2 PO 4 , 25 mM NaHCO 3 ), supplemented with 5 mM EGTA. Prior to infusion of these solutions, animals were anaesthetized with ~2% isoflurane, shaved, and mounted in a rodent stereotaxic device (David Kopf Instruments); heart rates and blood oxygenation were monitored by a pulse oximeter (Nonin Medical). Each animal's scalp was retracted and 28 G holes were drilled into the skull above desired injection sites. 28 guage cannula guides (Plastics One) that projected 2 mm below the surface of the skull were implanted using SEcure light curing dental cement (Parkell) and 33 guage metal injection cannulae that projected 5 mm below the skull were lowered to the appropriate depth through the holes. All the injections were targeted to the caudate nucleus, coordinates 1 mm anterior, 3 mm lateral and 5 mm ventral to the bregma, chosen based on a standard rat-brain atlas 34 . Nanoparticle infusions were performed using an injection rate of 0.12 µ l min -1 for 1 h with the control and test sides alternated for each experiment to negate potential artefacts or bias. Metal cannulae were then removed and the animals were transferred to an MRI rat-imaging cradle (Bruker). Plastic cannulae for the delivery of the control and stimulatory agents during MRI were then lowered bilaterally through the guide cannulae to the contrast-agent delivery sites, and subsequently fixed in place with ETC light-curing dental cement (Parkell).
Calcium-dependent molecular fMRI with chemical brain stimulation. In vivo MRI measurements were obtained using a 9.4 T Biospec MRI scanner (Bruker) operated with a cross-coil volume transmit, surface-receive configuration. Rapid acquisition with refocused echoes (RARE) pulse sequences were used to acquire T 2 -weighted anatomical and functional images. Imaging parameters for anatomical images included a number of averages = 6, matrix size = 300 × 200, FOV = 3 cm × 2 cm, slice thickness = 1.2 mm, TR = 5,000 ms, effective TE = 60 ms, and RARE factor = 8. The imaging parameters for the functional imaging scan series were matrix size = 75 × 50, FOV = 3 cm × 2 cm, slice thickness = 1.2 mm, TR = 3,000 ms, effective TE = 90, and RARE factor = 8. The acquisition time per image frame was 12 s. Chemical stimuli delivered during molecular fMRI experiments consisted of pulsed injections of complete aCSF supplemented by 100 mM KCl, 100 mM NaCl (control) or 1 mM glutamate, and delivered at a rate of 0.12 µ l min -1 during continuous image acquisition. Each experiment consisted of a Letters Nature NaNotechNology 2 min pre-stimulation period, followed by 5 min of stimulation and 10 min of rest. Three stimulations were performed for each animal.
Calcium-dependent molecular fMRI with electrical brain stimulation. Rats were purchased with pre-implanted jugular catheters (Charles River Laboratories). After acclimation, unipolar electrodes were implanted bilaterally into the MFB. Guide cannulae for striatal sensor infusion were implanted as described above, and headposts to fix the heads in place during the imaging were attached above the sagittal suture using dental cement. The rats were allowed 3-7 d for recovery, and then anaesthetized and infused with MaCaReNa sensor doses as per previous methods. The animals were then intubated via a tracheotomy, transferred to lighter chemical anaesthesia with 1 mg kg -1 intraperitoneal (i.p.) medetomidine and paralysed with pancuronium (2 m kg -1 i.p.) to prevent motion artefacts during the stimulation. On paralysis, the animals were transferred to a small animal respirator (Harvard Apparatus Inspira) and fixed, via their headposts, into a custom-built cradle for imaging. Once positioned in the magnet, medetomidine (1 mg -1 kg h -1 ) and pancuronium (2 mg kg -1 h -1 ) were delivered continuously via an i.p. catheter, along with N ω -nitro-l-arginine methyl ester (100 mg kg -1 h -1 intravenously) to suppress the haemodynamic signals. After 45 min of acclimation to these conditions, functional imaging was performed using T 2 -weighted spin-echo echoplanar imaging (TE = 60 ms, TR = 4 s). During each animal's scan session, the stimulation was applied in five epochs that consisted of a 2 min baseline, 24 s MFB stimulation (0.3 mA, 200 Hz, 1 ms pulses, 75% duty cycle that consisted of 3 s trains separated by 1 s between trains) and then 5 min of recovery before the next epoch.
Electrophysiology with electrical brain stimulation. Animals were prepared similarly to those for the MRI studies. Immediately after implantation of the stimulation electrodes, the animals were paralysed, and their anaesthesia was switched to medetomidine. Using a micromanipulator Sutter Instrument Company MP-285, a 16-channel laminar probe (Neuronexus Technologies A1x16-10mm-100-177-A16) was lowered into the dorsal striatum (~5 mm) through a previously drilled craniotomy (0.2 mm anterior and 3.0 mm lateral to the bregma). Extracellular signals recorded via the electrodes were amplified using a 1 × gain headstage (Plexon model E2a) connected to a 50 × preamp (Plexon PBX-247) and digitized at 50 kHz. A 250 Hz high-pass filter was applied to the raw signal, and single units were sorted using the Offline Sorter software (Plexon) based on their principal components, peak valley and non-linear energy ratio prior to sorting units. Time stamps of the sorted units were exported to MATLAB and post-stimulus time histograms and further statistics were computed using custom procedures. The sample sizes of neurons were chosen such that between-group comparisons provided a power of 0.95 and significance was defined by two-tailed t-tests with α = 0.05.
Behavioural assessment of intracranial self-stimulation.
Behaviour experiments were performed in a 28 × 21 × 21 cm plexiglass operant chamber (Lafayette Instruments). One infrared nose-poke sensor was positioned at one end of the operant chamber. Input from the nose-poke sensor was recorded via a digital input/output interface (National Instruments). This input triggered MFB stimulation in 3 s trains of 200 Hz, 0.3 mA and 1 ms electrical pulses, identical to the stimuli used in the fMRI experiments. Two animals were shaped to the task and then tested over ten 60 s trials each, with an intertrial interval of 10 s. Input and output events for every trial were recorded and analysed by custom-written computer scripts implemented in C and MATLAB to generate the data presented in Supplementary Fig. 7 .
MRI data analysis. Images were reconstructed using Paravision software (Bruker) and further analysed using custom routines implemented in MATLAB. For the quantitative analysis of signal changes induced by the injection of MaCaReNas, LCIOs or LCIO/C2AB Ca− mixtures (Fig. 2) , regions of interest (ROIs) were determined by manually selecting the centroids of the apparent nanoparticleinduced hypointensity from MRI images. Signal-change values were determined by averaging the observed intensities within a 3 × 3 pixel (1.2 × 1.2 mm) square around these centroids. In each case, the percent signal change (%SC) was determined as the difference between mean MRI intensity in each injection site ROI (S inj ) and the mean intensity in a reference ROI positioned medial to the infusion zones ( Quantitative analysis of the chemical stimulus-induced molecular fMRI signal changes ( Fig. 3) was performed on data converted on a per-voxel basis to %SC from baseline, according to the relationship %SC = 100 × [S(t) -S base ]/S base , where S(t) is the signal at any arbitrary time point and S base is the mean signal observed during the 2 min pre-stimulation period. Signal time courses for each animal were determined by manually selecting a brain hemisphere and then using an operatorblind algorithm to identify the centroids of apparent nanoparticle-induced hypointensity from the MRI images. This ROI was defined around the pixel of peak signal change averaged over 2 min, centred at the endpoint of injection and averaging the %SC values around this pixel over a 1.2 × 1.2 mm square ROI. These time courses were temporally smoothed over a moving window of 1 min, baseline corrected to remove linear drift (for multiple stimulus experiments only) and each series of stimulus responses was averaged over multiple animals to obtain the mean time courses and corresponding s.e.m. for each experimental condition. %SC amplitudes for each stimulus type were defined as %SC = 100 × (S stim -S base )/S base , where S base is the MRI signal intensity observed during the 2 min pre-stimulus baseline and S stim is the MRI signal observed during a 2 min window around the stimulant infusion offset time. Signal-change slopes associated with the response to and recovery from stimulation were determined by linear fitting to the 5 min stimulant infusion periods and 10 min post-infusion periods, respectively. The distributions of signal-change amplitudes and slope values from multiple animals are presented as box plots. Only experimental sessions that were prematurely terminated due to major technical failures were excluded from analysis.
For the MFB stimulation experiments of Fig. 4 , baseline measurements, conversion to %SC and ROI selection were again performed as described above. Responses to all five stimuli presented to each animal were averaged together before the ROI analysis, and ROIs were centred around the pixel of maximum response within a 20 s window centred about the endpoint of the stimulation. Stimulation traces from each animal were averaged and smoothed over a 20 s window; the traces presented in Fig. 4c represent the mean and s.e.m. time courses from multiple animals. The %SC amplitudes presented in Fig. 4d were defined as %SC = 100 × (S stim -S base )/S base , where S base is the mean baseline MRI signal intensity and S stim is the MRI signal observed during a 60 s window beginning at the stimulus offset time; box plots depict data from multiple animals.
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Experimental design 1. Sample size
Describe how sample size was determined.
Sample sizes for all animal experiments were chosen such that between-group comparisons provided a power of 0.8 when detecting 10% signal differences between groups using twotailed t-tests.
Data exclusions
Describe any data exclusions.
Only experimental sessions that were prematurely terminated due to major technical failures were excluded from analysis.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All experiments were performed with multiple replicates, and standard statistical methods were used to accept or reject null hypotheses of no effect.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups. n/a
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis. n/a Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
